Business Context and Reporting Period
This Form 8-K, dated September 20, 2024, is filed by Reneo Pharmaceuticals, Inc. (the "Company") regarding its proposed merger with OnKure, Inc. Upon consummation, the Company will change its name to OnKure Therapeutics, Inc. The filing serves as a supplement to the previously filed Proxy Statement/Prospectus (Form S-4) to address allegations made in two shareholder lawsuits filed in September 2024 challenging the merger's financial projections and advisor conflicts.
Key Financial Metrics and Projections
The filing does not report historical revenue, profit, or cash flow for the current period. Instead, it discloses unaudited financial forecasts for OnKure used in the merger valuation:
- Valuation Range: Leerink Partners' discounted cash flow analysis implied an equity value for OnKure of approximately $180.0 million to $290.0 million.
- Merger Consideration: The proposed transaction involves approximately 76.959 million shares of Reneo Common Stock.
- OnKure Cash Position: OnKure's estimated net cash balance as of September 30, 2024, is $0.0 million.
- Reneo Cash Position: Reneo anticipated an approximately $60 million closing net cash position.
- Revenue Forecasts (Unadjusted): OnKure projects Net Sales of $11 million in 2033, growing to $3,031 million by 2042.
- Profitability Forecasts (Unadjusted): OnKure projects Unadjusted Operating Income turning positive in 2033 ($255 million) and reaching $2,217 million by 2042.
- Advisor Fees: Co-placement agents (Leerink Partners, Evercore, LifeSci Capital) are entitled to aggregate compensation of 5% of the gross proceeds of the Concurrent PIPE Investments.
Material Changes and Litigation
The primary material event is the filing of two shareholder complaints in the Supreme Court of the State of New York (Thomas v. Reneo and Kent v. Reneo) alleging misrepresentation regarding financial projections and conflicts of interest with financial advisors. In response, Reneo voluntarily supplemented disclosures to clarify:
- Special Committee Formation: The Reneo Board formed a Special Committee of independent directors to negotiate the transaction after identifying potential conflicts with outside counsel (Cooley) regarding Party A.
- Advisor Conflicts: Leerink Partners received approximately $40,000 in the past two years for at-the-market sales services and will serve as a placement agent for the PIPE. Leerink has not provided services to OnKure in the past two years.
- Valuation Methodology: Clarification that Leerink Partners relied on OnKure Forecasts directed by Reneo management, including probability of success (POS) adjustments, and did not prepare separate forecasts for Reneo or conduct a liquidation analysis for Reneo.
- Executive Compensation: All unvested options and RSUs held by Reneo directors and officers (covering 772,406 shares and 185,000 shares respectively) will vest upon the closing of the merger.
Guidance, Outlook, and Risks
Management Commentary: Reneo denies the allegations in the lawsuits and asserts that the Proxy Statement/Prospectus complies with all applicable laws. The Board believes the merger creates greater value than liquidation, citing the need to retain cash for liabilities and the potential future value of the combined company.
Risks and Contingencies:
- Litigation Risk: The lawsuits seek to enjoin the merger or award damages; additional lawsuits may be filed before consummation.
- Forecast Reliance: Investors are cautioned not to place undue reliance on the supplemental unadjusted forecasts, which are not GAAP measures and do not include a reconciliation to GAAP.
- Transaction Risk: The merger is subject to conditions including stockholder approval and regulatory clearance. Failure to close could result in termination.
- Development Risk: The combined company relies on the development of OnKure's lead product candidate, OKI-219, which faces clinical and regulatory uncertainties.
Investor Verification Checklist
- Verify the status of the pending shareholder lawsuits (Thomas v. Reneo and Kent v. Reneo) and any court orders issued.
- Review the full Proxy Statement/Prospectus (Form S-4) for the complete details of the merger terms and the fairness opinion.
- Confirm the final terms of the Concurrent PIPE Investments and the total capital raised.
- Assess the validity of the OnKure financial forecasts, particularly the assumptions regarding the probability of success for OKI-219 and the 50% annual decline in cash flows post-patent expiration.
- Monitor the composition of the NewCo Board, noting that Reneo executive officers are not expected to be employed by the combined company post-closing.